[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335976-105":59,"doc-detail-335976-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","phase-i-trial-of-first-line-bintrafusp-alfa-in-patients-with-locally-advanced-or-persistentrecurrentmetastatic-cervical-cancer","Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer","","First-line bintrafusp alfa, a bifunctional TGFβ trap fused to an anti–PD-L1 IgG1 mAb, was evaluated for locally advanced or persistent/recurrent/metastatic cervical cancer. In a multicenter open-label phase Ib study (NCT04551950), patients received bintrafusp alfa with either cisplatin/carboplatin plus paclitaxel ± bevacizumab, or with cisplatin plus radiation followed by maintenance. Safety was primary; efficacy and pharmacokinetics were secondary. Results showed manageable toxicity, with objective responses and clinically meaningful activity supporting TGFβ/PD-L1 inhibition in HPV-associated cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phase-i-trial-of-first-line-bintrafusp-alfa-in-patients-with-locally-advanced-or-persistentrecurrentmetastatic-cervical-cancer/335976/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phase-i-trial-of-first-line-bintrafusp-alfa-in-patients-with-locally-advanced-or-persistentrecurrentmetastatic-cervical-cancer/335976.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is bintrafusp alfa and what mechanism is evaluated in this trial?","Question",{"text":112,"@type":113},"Bintrafusp alfa is a bifunctional fusion protein combining a TGFβ receptor II extracellular domain “trap” with an IgG1 monoclonal antibody blocking PD-L1. The study evaluates its use as a first-line treatment in cervical cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was bintrafusp alfa administered in different patient cohorts?",{"text":117,"@type":113},"Cohorts 1A and 1B received bintrafusp alfa 2,400 mg every 3 weeks with cisplatin or carboplatin plus paclitaxel, with cohort 1A also including bevacizumab. Cohort 2 received bintrafusp alfa 2,400 mg every 3 weeks with cisplatin plus radiation, followed by bintrafusp alfa maintenance monotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the primary and secondary endpoints?",{"text":121,"@type":113},"The primary endpoint was safety. Secondary endpoints included efficacy (including objective response rate) and pharmacokinetics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335976,1790813831,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer  \nAna Oaknin1, Sharad A. Ghamande2, Yuka Kasamatsu3, Marta Gil-Martin4, Juan Francisco Grau-Bejar1, Carmen Garcia-Duran1, Masashi Sato5, Abdul Siddiqui5, Surendra Pal Chaudhary6, Yulia Vugmeyster6, and Kosei Hasegawa7  \nABSTRACT  \n◥  \nPurpose: Bintrafusp alfa, a ﬁrst-in-class bifunctional fusion protein composed of the extracellular domain of TGFb receptor II (a TGFb “trap”) fused to a human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment inpatients with locally advanced or persistent, recurrent, or metastatic (P/R/M) cervical cancer.  \nPatients and Methods: In this multicenter, open-label, phase Ib trial (NCT04551950), patients with P/R/M cervical cancer received bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with (Cohort 1A; n ¼ 8) or without (Cohort 1B; n ¼ 9) bevacizumab; patients with locally advanced cervical cancer received bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2; n ¼ 8). The primary endpoint was safety; secondary endpoints includedefﬁcacy (including objective response rate) and pharmacokinetics.  \nResults: At the data cutoff of April 27, 2022, patients in Cohorts 1A, 1B, and 2 had received bintrafusp alfa for a median duration of 37.9, 31.1, and 16.7 weeks, respectively. Two dose-limiting toxicities (grade 4 amylase elevation and grade 3 menorrhagia) unrelated tobintrafusp alfa were observed in Cohort 1B and none in other cohorts. Most treatment-emergent adverse events of special interest were grades1–2in severity, most commonly anemia(62.5%–77.8%) and bleeding events (62.5%–77.8%) . Objective response rate was 75.0%[95% conﬁdence interval (CI), 34.9–96.8], 44.4%(95% CI, 13.7–78.8), and62.5%(95%CI,24.5–91.5)in Cohorts1A,1B, and2, respectively.  \nConclusions: Bintrafusp alfa had manageable safety and demonstrated clinical activity, further supporting the investigation of TGFb/PD-L1 inhibition in human papillomavirus–associated cancers, including cervical cancer.  \nIntroduction  \nPersistent human papillomavirus (HPV) infection is implicated in 99% of cervical cancers and is linked to activation of TGFb and programmed death-ligand 1 (PD-L1) signaling pathways (1–3) . The standard-of-care treatment for locally advanced cervical cancer, deﬁned as IB3-IVA by the International Federation of Gynecology and Obstetrics (FIGO 2018), is concurrent chemoradiation with weekly cisplatin (4), with newer treatment approaches failing to improve current long-term outcomes (5, 6) . Both the OUTBACK trial (for adjuvant chemotherapy after chemoradiation; NCT01414608) and the CALLA trial (for durvalumab, a mAb targeting PD-L1, in combination with concurrent chemoradiotherapy;NCT03830866)did not demonstrate improved long-term clinical outcomes for these  \n1Gynaecologic Cancer Programme, Vall d’ Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’ Hebron, Vall d’ Hebron Barcelona Hospital Campus, Barcelona, Spain. 2Augusta University, Augusta, Georgia. 3Shizuoka Cancer Center, Suntogun, Japan. 4Institut Catal d’Oncologia-IDIBELL, L’ Hospitalet de Llobregat, Barcelona, Spain. 5the healthcare business of Merck KGaA, Darmstadt, Germany. 6EMD Serono, Billerica, Massachusetts. 7Saitama Medical University International Medical Center, Saitama, Japan.  \nCorresponding Author: Ana Oaknin, Valld’ Hebron Institute of Oncology(VHIO), Hospital Universitari Vall d’ Hebron, Vall d’ Hebron Barcelona Hospital Campus,  \nBarcelona 08035, Spain. E-mail: [aoaknin@vhio.net](aoaknin@vhio.net)  \n[Clin Cancer Res 2024](Clin Cancer Res 2024);[30:975](30:975)–[83](83)  \n[doi:](doi: 10.1158/1078-0432.CCR-23-1829)[ 10.1158/1078-0432.CCR-23-1829](doi: 10.1158/1078-0432.CCR-23-1829)  \nThis open access article is distributed under the Creative Commons AttributionNonComme","cbCaiaLXGt69i4l3","https://ap.wps.com/l/cbCaiaLXGt69i4l3","pdf",490937,"English","# Purpose\n# Patients and Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is bintrafusp alfa and what mechanism is evaluated in this trial?\",\"answer\":\"Bintrafusp alfa is a bifunctional fusion protein combining a TGFβ receptor II extracellular domain “trap” with an IgG1 monoclonal antibody blocking PD-L1. The study evaluates its use as a first-line treatment in cervical cancer.\"},{\"question\":\"How was bintrafusp alfa administered in different patient cohorts?\",\"answer\":\"Cohorts 1A and 1B received bintrafusp alfa 2,400 mg every 3 weeks with cisplatin or carboplatin plus paclitaxel, with cohort 1A also including bevacizumab. Cohort 2 received bintrafusp alfa 2,400 mg every 3 weeks with cisplatin plus radiation, followed by bintrafusp alfa maintenance monotherapy.\"},{\"question\":\"What were the primary and secondary endpoints?\",\"answer\":\"The primary endpoint was safety. Secondary endpoints included efficacy (including objective response rate) and pharmacokinetics.\"}]","Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer | PDF",1790013022,23]